vTv Therapeutics Inc. (NASDAQ:VTVT) Short Interest Down 17.3% in November

vTv Therapeutics Inc. (NASDAQ:VTVT) was the recipient of a significant decrease in short interest during the month of November. As of November 30th, there was short interest totalling 22,500 shares, a decrease of 17.3% from the November 15th total of 27,200 shares. Approximately 1.6% of the company’s stock are sold short. Based on an average trading volume of 31,300 shares, the short-interest ratio is currently 0.7 days.

Analyst Upgrades and Downgrades

Separately, Alliance Global Partners assumed coverage on shares of vTv Therapeutics in a research report on Monday, December 9th. They set a “buy” rating and a $35.00 price objective on the stock.

vTv Therapeutics Price Performance

Shares of NASDAQ:VTVT opened at $15.03 on Monday. vTv Therapeutics has a 1 year low of $7.38 and a 1 year high of $30.99. The company has a market cap of $47.95 million, a P/E ratio of -3.32 and a beta of 0.67. The stock’s fifty day moving average price is $14.94 and its 200-day moving average price is $16.40.

Institutional Trading of vTv Therapeutics

An institutional investor recently bought a new position in vTv Therapeutics stock. FMR LLC acquired a new stake in shares of vTv Therapeutics Inc. (NASDAQ:VTVT) in the third quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The institutional investor acquired 178,200 shares of the biotechnology company’s stock, valued at approximately $2,402,000. FMR LLC owned about 5.92% of vTv Therapeutics as of its most recent filing with the Securities and Exchange Commission (SEC). 17.51% of the stock is currently owned by institutional investors.

vTv Therapeutics Company Profile

vTv Therapeutics Inc, a clinical stage biopharmaceutical company, focuses on the development of orally administered treatments for metabolic and inflammatory diseases. The company's lead drug candidate is cadisegliatin (TTP399), an orally administered small molecule and liver-selective glucokinase activator that is in Phase III clinical trial for treating type 1 and type 2 diabetes; and TTP273, an orally available small molecule glucagon-like peptide 1 receptor agonists that is in Phase I clinical trial for the treatment of cystic fibrosis related diabetes, as well as in Phase II trial for the treatment of type 2 diabetes.